IP Library Patent Application 15581258
Patent Application
App. No. 15/581,258

METHODS OF MONITORING ADHERENCE TO QUETIAPINE THERAPY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/581,258
Abstract

The present disclosure provides methods for monitoring subject (e.g., patient) adherence to quetiapine therapy, for example as a component of treating a subject for a mental health disorder such as schizophrenia, bipolar disorder or major depressive disorder.

Claims (31)

1 . A method for detecting quetiapine in a fluid sample obtained from a subject that has been prescribed quetiapine comprising:

detecting a quetiapine metabolite in the fluid sample via QQQ mass spectrometry or Q-ToF mass spectrometry; and

detecting quetiapine in the fluid sample when at least 5 ng/mL of the quetiapine metabolite is detected in the sample, wherein the quetiapine metabolite is one or more of quetiapine, quetiapine sulfoxide, N-desalkylquetiapine, 7-hyroxyquetiapine, 7-hydroxyquetiapine glucuronide, quetiapine carboxylic acid, quetiapine glucuronide, quetiapine sulfoxide glucuronide, and quetiapine carboxylic acid glucuronide.

2 . (canceled)

3 . (canceled)

4 . The method of claim 1 , wherein about 5 ng/mL, about 20 ng/mL, or about 50 ng/mL is detected in the fluid sample.

5 . The method of claim 1 , wherein the fluid sample is a urine sample.

6 . (canceled)

7 . The method of claim 1 , wherein the quetiapine metabolite is two or more of: quetiapine, quetiapine sulfoxide, N-desalkylquetiapine, 7-hyroxyquetiapine, 7-hydroxyquetiapine glucuronide, quetiapine carboxylic acid, quetiapine glucuronide, quetiapine sulfoxide glucuronide, and quetiapine carboxylic acid glucuronide.

8 . The method of claim 1 , wherein the quetiapine metabolite is three or more of: quetiapine, quetiapine sulfoxide, N-desalkylquetiapine, 7-hyroxyquetiapine, 7-hydroxyquetiapine glucuronide, quetiapine carboxylic acid, quetiapine glucuronide, quetiapine sulfoxide glucuronide, and quetiapine carboxylic acid glucuronide.

9 . The method of claim 1 , wherein the quetiapine metabolite is four or more of: quetiapine, quetiapine sulfoxide, N-desalkylquetiapine, 7-hyroxyquetiapine, 7-hydroxyquetiapine glucuronide, quetiapine carboxylic acid, quetiapine glucuronide, quetiapine sulfoxide glucuronide, and quetiapine carboxylic acid glucuronide.

10 . (canceled)

11 . (canceled)

12 . The method of claim 1 further comprising contacting the fluid sample with a hydrolyzing enzyme before detecting the presence of the quetiapine metabolite in the fluid sample.

13 . The method of claim 12 , wherein the hydrolyzing enzyme is a glucuronidase enzyme.

14 . The method of claim 13 , wherein the glucuronidase enzyme is a recombinant β-glucuronidase enzyme.

15 . (canceled)

16 . (canceled)

17 . (canceled)

18 . A method for detecting quetiapine in a fluid sample obtained from a subject that has been prescribed quetiapine comprising:

detecting a quetiapine metabolite in the fluid sample via QQQ mass spectrometry or Q-ToF mass spectrometry, wherein the fluid sample has been hydrolyzed; and

detecting quetiapine in the fluid sample when at least 5 ng/mL of the quetiapine metabolite is detected in the sample, wherein the quetiapine metabolite is one or more of quetiapine, quetiapine sulfoxide, 7-hyroxyquetiapine, and quetiapine carboxylic acid.

19 . The method of claim 18 , wherein the fluid sample is hydrolyzed by contacting the fluid sample with a composition comprising a glucuronidase enzyme.

20 . The method of claim 19 , wherein the glucuronidase enzyme is a recombinant β-glucuronidase enzyme.

21 . (canceled)

22 . The method of claim 18 , wherein the hydrolyzed fluid sample does not contain any one of quetiapine, quetiapine sulfoxide, 7-hyroxyquetiapine, and quetiapine carboxylic acid in an amount that is greater than 5 ng/mL.

23 . (canceled)

24 . (canceled)

25 . (canceled)

26 . The method of claim 1 , wherein the subject has been prescribed a quetiapine dose selected from the group consisting of 800 mg/day, 600 mg/day, 400 mg/day, 300 mg/day, 200 mg/day, 150 mg/day, 100 mg/day, 50 mg/day, and 25 mg/day.

27 . The method of claim 18 , wherein the subject has been prescribed a quetiapine dose selected from the group consisting of 800 mg/day, 600 mg/day, 400 mg/day, 300 mg/day, 200 mg/day, 150 mg/day, 100 mg/day, 50 mg/day, and 25 mg/day.